1. New ELN Recommendations

3. 2017 ELN Guidelines: Overview

4. 2016 Updated WHO Classification of AML

5. Molecular Landscape of AML

6. Molecular Classification of AML: Implications for Diagnosis

7. Diagnostic Workup of AML: Practical Considerations

8. Risk Stratification and Treatment Selection

9. Indications for Allogeneic Transplantation

10. Targeted Therapies for AML: Targeting FLT3

11. Targeted Therapies for AML: Targeting IDH2

12. Measurable/Minimal Residual Disease

13. Using MRD During Treatment to Assess Early Response

14. Using MRD After Treatment to Detect Early Relapse: Example From APL

15. Using MRD After Treatment to Detect Early Relapse: Example From CBF-AML

16. Prognostic Significance of FLT3-ITD Mutation vs MRD Status

17. Using MRD Status to Guide Treatment Selection

18. Prognostic Significance of Age vs Comorbidities/Performance Status

19. Selecting a Non-Intensive Treatment Approach

20. Assessing Response to Hypomethylating Agents

21. Azacitidine in Older Patients With AML 30+: AZA-AML-001 Phase 3 Trial

22. Outcomes With Azacitidine in Patients Who Do Not Achieve CR: AZA-AML-001

23. Managing Toxicities Associated With Hypomethylating Agents

24. Decitabine in Older Patients With AML: DACO-016 Phase 3 Trial

25. Outcomes With Decitabine in Patients With Baseline Hyperleukocytosis: DACO-016

26. Conclusions

27. Abbreviations

28. Abbreviations (cont)

29. Abbreviations (cont)